Interferon-alpha inhibits in vitro osteoclast differentiation and renal cell carcinoma-induced angiogenesis.
Bone is a common site of osteolytic and richly vascularized metastases of renal cell carcinoma (RCC) and Interferon (IFN)-alpha based therapies have been considered for the treatment of patients affected by this disease. The effects of IFN-alpha on metastatic RCC patients have been related to its immunomodulatory, and cytotoxic activity on tumor cells, but there could be an effect also on tumor induced osteoclast differentiation and bone angiogenesis. When osteoclasts obtained from human peripheral blood mononuclear cells, cultured in the presence of receptor activator of nuclear factor-kappaB (RANKL) and macrophage-colony stimulating factor (M-CSF), were treated with IFN-alpha, the expression of bone tartrate resistant acid phosphatase (TRACP) type 5b was reduced, as well as calcium-phosphate resorption activity and expression of pro-osteoclatic transcription factor c-Fos. IFN-alpha modulation of angiogenesis was studied by analysis of proliferation, survival, and migration of a bone endothelial cell line (BBE), and by the analysis of pro-angiogenic factor expression in RCC cell lines. IFN-alpha inhibited bone endothelial cell proliferation and the expression of FGF-2, while the vascular endothelial growth (VEGF) did not show any significant variation. Moreover, IFN-alpha inhibited the migration induced by the RCC through the impairment of fibroblast growth factor-2 (FGF-2) secretion. These data demonstrate multiple activities of IFN-alpha on renal cancer-induced bone disease, in addition to its recognized role as a cytotoxic and immunomodulatory agent, because they indicate its ability to reduce bone resorption and to impair tumor-associated angiogenesis, and they also suggest the use of IFN-alpha to treat skeletal metastases of other carcinomas.
Avnet
S
S
Laboratory for Pathophysiology of Orthopaedic Implants, Istituti Ortopedici Rizzoli, I-40136 Bologna, Italy. sofia.avnet@ior.it
Cenni
E
E
Perut
F
F
Granchi
D
D
Brandi
M L
ML
Giunti
A
A
Baldini
N
N
D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D002292:Carcinoma, Renal Cell / Q000378:metabolism*; D002454:Cell Differentiation; D002633:Chemotaxis; D018450:Disease Progression; D016222:Fibroblast Growth Factor 2 / Q000096:biosynthesis / Q000378:metabolism; D005347:Fibroblasts / Q000378:metabolism; D006801:Humans; D016898:Interferon-alpha / Q000378:metabolism / Q000502:physiology*; D007680:Kidney Neoplasms / Q000378:metabolism*; D008264:Macrophages / Q000378:metabolism; D009362:Neoplasm Metastasis; D009389:Neovascularization, Pathologic; D010010:Osteoclasts / Q000378:metabolism*; D016760:Proto-Oncogene Proteins c-fos / Q000378:metabolism; D013997:Time Factors; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
D020533:Angiogenesis Inhibitors; D016898:Interferon-alpha; D016760:Proto-Oncogene Proteins c-fos; D042461:Vascular Endothelial Growth Factor A; D016222:Fibroblast Growth Factor 2